INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 446m ago
HOUSE PTR46m ago
SEC 13F46m ago
ROBINHOOD CHAIN45m ago
SEC FORM 4/Derivative conversionVerified data

Hahn Stephen M. reported FTH

Director · Faeth Therapeutics, Inc. · Sensei Biotherapeutics, Inc. — Series B Preferred Stock

Side
C
Value
—
Shares
44.76
Price
—
Executed
Jun 15, 2026
Disclosed
Jun 16, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jun 15 executedJun 16, 2026 disclosed

FTH · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Derivative conversion — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · FTH

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    8
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Gift
    		G—
    100.0K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    12
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Gift
    		G—
    100.0K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SA
    Schayowitz AdamDirector
    FTHFaeth Therapeutics, Inc.
    Grant or award
    		A—
    25.0K sh
    		Oct 23, 2026Oct 27, 2026
    traded Oct 23, 2026
    		+4dSEC FORM 4

    Evidence

    9
    VH
    Vousden Karen HDirector
    FTHFaeth Therapeutics, Inc.
    Grant or award
    		A—
    25.0K sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$105K
    4,212 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    27
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$2,777
    100 sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    27
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$2,639
    100 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$73K
    2,891 sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$92K
    3,400 sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$78K
    3,000 sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    27
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$35K
    1,358 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    27
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$14K
    580 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    9
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Option exercise
    		M$9,527
    8,213 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    21
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Option exercise
    		M—
    45.3K sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    46
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$23K
    1,118 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    46
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$36K
    1,797 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    46
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$35K
    1,583 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    49
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$77K
    3,329 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$8,526
    356 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    45
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$165K
    6,836 sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002137706-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 15, 2026
    Published
    Jun 16, 2026
    Ingested by INSIDER
    Nov 5, 03:52 UTC
    Last re-read
    Nov 5, 03:52 UTC

    Extracted facts

    Filer
    Hahn Stephen M.
    Role
    Director
    Transaction
    Derivative conversionAs filed: “C”
    Asset
    Sensei Biotherapeutics, Inc. — Series B Preferred Stock
    Ticker
    FTH
    Shares
    44.76
    Execution date (reported)
    Jun 15, 2026
    Owned after transaction
    0 shares
    Days from execution to publication
    1

    What this establishes

    Hahn Stephen M. filed this Form 4 reporting a derivative conversion of FTH on Jun 15, 2026. It became public on Jun 16, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Hahn Stephen M.cik:0002137706
    Issuer
    Faeth Therapeutics, Inc.cik:0001829802

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.